Determination of the optimal obesity‐adjusted dosing weight for enoxaparin
Compared to IBW + 40% or LBW + 40% use of ABW to calculate dose was poorly associated with factor anti-Xa levels, as was IBW or LBW. IBW + 40% and LBW + 40% require further study as a dosing weight metric and may provide a more consistent factor anti-Xa response in those with obesity.
Authors
- D. B. Williams (ORCID: https://orcid.org/0000-0002-5954-2694)
- Viviane Caceres (ORCID: https://orcid.org/0000-0002-6052-0273)
- Anthony Damiani
- Patrick Russell (ORCID: https://orcid.org/0000-0002-2534-3371)
- Nicholas L. Scarfo (ORCID: https://orcid.org/0000-0002-4344-9284)
- G.W. Roberts (ORCID: https://orcid.org/0000-0002-8669-5944)
Institutions
- Royal Adelaide Hospital (AU)
- University of South Australia (AU)
- SA Health (AU)
- Central Adelaide Local Health Network
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1111/bcp.16338
- Citations
- 2
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.10